[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Benef](https://github.com/mm80843/T3.5/tree/main/docs/Benef/index.md) >> Individual ID:PBN__Benef_405 

# __Suppression of transmission__

## Articles mentionning this Benefit

* [Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand](https://github.com/mm80843/T3.5/blob/pages/Article/PBN__Article_80.md)

## Category to which it belongs

* [Mitigated transmission of diseases through various means, such as reduced airborne and aerosol transmission, and improved understanding and prevention of transmission.](https://github.com/mm80843/T3.5/blob/pages/PBNCategory/PBN__PBNCategory_35.md)

## Description of actual returns pertaining to this benefit

* [Private investors could benefit by investing in a comprehensive approach to reduce transmission as it would contribute to a healthier population, decreased healthcare demand, and potentially provide economic stability by preventing a prolonged epidemic and the associated economic disruptions.](https://github.com/mm80843/T3.5/blob/pages/BenefReturn/PBN__BenefReturn_435.md)

## Name of the Benefit

Results in a significant impact on reducing transmission rates and controlling the spread of the virus

## Risks which can benefit from this action

* [Combination of multiple interventions](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_409.md)

## Stakeholders benefitting from this Benefit

* [General population](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_9.md)

